Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban for Vein Graft Patency Post-CABG
NCT01246011Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of argatroban in vein graft occlusion (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Coronary Artery Bypass Vein Graft Patency at 30 days. Started Nov 2010; status: terminated.
02
Drugs
argatroban
03
Conditions
vein graft occlusion
Beyond the preview
Go deeper on NCT01246011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01246011.